NCT05002140View on ClinicalTrials.gov

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

July 21, 2023

Study Completion Date

July 21, 2023

Conditions

MetastasisLocally Advanced Solid TumorRecurrent Cancer

Interventions

DRUG

XRD-0394

Single ascending dose

RADIATION

Palliative radiotherapy

4 Gy × 5 daily fractions

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

94305

Stanford Clinical Cancer Center, Stanford

All Listed Sponsors

lead

XRad Therapeutics Inc

INDUSTRY

NCT05002140 - Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | Biotech Hunter | Biotech Hunter